Clinical trial · Observational
A Study of Prevalence of EGFR Mutations in Participants With NSCLC
An Epidemiology Study of the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients Diagnosed With Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT02695849CI-TRIAL-00022820completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in participants diagnosed with non-squamous non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- NSCLC Participants
- description
- Participants with non-squamous NSCLC will be enrolled in this study.
Primary outcomes (1)
- measure
- Percentage of Participants with EGFR mutations
- timeFrame
- Day 1
Secondary outcomes (1)
- measure
- Percentage of Participants with types of EGFR mutations
- timeFrame
- Day 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Informed consent form signature * Jordanian male and female participants greater than or equal to (\>=) 18 years of age * Histologically confirmed NSCLC * Not participating in a study that involves an investigational agent within 30 days prior to enrollment Exclusion Criteria: * Other primary malignancy * Fine needle aspiration samples
References
Publications (0)
Data not yet available
No reference posted for this study.